Skip to main content
logo
Cellromax Science Co., Ltd. (KOSDAQ:471820)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,970.00
+60.00 (1.53%)
At close: Nov 3, 2026

Cellromax Science Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Revenue
19,60422,18421,630
Revenue Growth
-16.01%2.56%-
Gross Profit
9,81410,54712,284
Operating Income
2,1532,8355,501
Net Income
3,0682,9663,817
Earnings Per Share
272.90261.00367.00
EPS Growth
41.27%-28.88%-

Revenue by Segment
Chart
Fiscal Year
TTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Health Food Division
16,53418,95919,505
General Pharmaceuticals Division
1,123937.36854.26
Cosmetics Division
1,3481,3471,160
Other
599.67940.7110.78
Total
19,60422,18421,630

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Cash & Investments
9,4247,70322,732
Total Debt
306.11477.831,498
Net Cash (Debt)
9,1187,22621,234
Net Cash Growth
-24.86%-65.97%-
Net Cash Per Share
808.09633.292041.44

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Operating Cash Flow
2,1751,7856,294
Capital Expenditures
-48.91-78.64-206.22
Free Cash Flow
2,1261,7076,088
Free Cash Flow Growth
-48.28%-71.97%-

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024
Period EndingJun '26 Dec '25 Dec '24
Gross Margin
50.06%47.54%56.79%
Operating Margin
10.98%12.78%25.43%
Pretax Margin
14.00%15.56%23.75%
Profit Margin
15.65%13.37%17.65%
FCF Margin
10.84%7.69%28.15%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024
Period EndingNov '26 Dec '25 Dec '24
PE Ratio
14.5524.8014.99
P/FCF Ratio
20.5343.119.40
PS Ratio
2.233.322.65